Aetna modified CPB 0957 for calaspargase pegol-mknl (Asparlas), effective November 6, 2025. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its calaspargase pegol coverage policy under CPB 0957 Aetna system. This change affects billing for IV chemotherapy administration under CPT codes 96413, 96414, and 96415 when Asparlas is used in pediatric and young adult ALL/LBL treatment protocols. If your practice treats patients 21 and under with acute lymphoblastic leukemia or lymphoblastic lymphoma, this update directly affects your prior authorization workflow and claim submission process.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Calaspargase Pegol-mknl (Asparlas) — CPB 0957 |
| Policy Code | CPB 0957 |
| Change Type | Modified |
| Effective Date | November 6, 2025 |
| Impact Level | High — pediatric oncology billing, specialty drug |
| Specialties Affected | Pediatric oncology, hematology/oncology, infusion centers |
| Key Action | Confirm age and multi-agent chemo documentation before submitting claims for Asparlas under CPT 96413–96415 |
Aetna Calaspargase Pegol Coverage Criteria and Medical Necessity Requirements 2025
The Aetna calaspargase pegol coverage policy under CPB 0957 is narrow and specific. Two hard criteria determine medical necessity. Miss either one and you're looking at a claim denial.
Aetna requires both of the following for initial approval:
| # | Covered Indication |
|---|---|
| 1 | Calaspargase pegol is used in conjunction with multi-agent chemotherapy — not as a standalone agent. |
| 2 | The member is 21 years of age or younger. |
That age cutoff is a firm line. A 22-year-old patient on an identical ALL treatment protocol does not meet medical necessity under this policy. Document the patient's date of birth clearly in every prior authorization request and on supporting clinical notes.
The multi-agent requirement matters too. Single-agent use is not covered, and Aetna will treat it as experimental. Your clinical documentation needs to show the full treatment regimen, not just the Asparlas order. If your oncology team submits a simplified treatment summary, the prior auth reviewer may not be able to confirm this criterion without a follow-up request — which delays everything.
For continuation of therapy, Aetna applies a cleaner standard. Continued treatment is medically necessary when there is no unacceptable toxicity and no disease progression on the current regimen. Your clinical team should document tolerability and response at each infusion visit. That documentation feeds directly into continuation auth requests.
This policy applies to commercial medical plans only. For Medicare criteria, Aetna directs you to the Medicare Part B step therapy criteria separately. Don't cross-apply commercial CPB 0957 criteria to Medicare-covered members — those are different standards.
Prior authorization is the practical reality here. Asparlas is a specialty drug with a narrow approved population. Aetna will require prior auth before reimbursement. Build that into your workflow before you schedule the first infusion.
Aetna Calaspargase Pegol Exclusions and Non-Covered Indications
Aetna is explicit: all indications outside of ALL and LBL in patients 21 and younger are experimental, investigational, or unproven.
That's a broad exclusion. If a provider attempts to use Asparlas in an adult patient, in a different cancer type, or as a single agent, Aetna will deny the claim under this standard. There's no gray area here.
The real exposure is off-label adult use. Calaspargase pegol has been studied in older adolescent and young adult populations. But Aetna's coverage policy draws the line at age 21. If your oncology program treats patients in the 22–39 age range under ALL protocols, confirm Aetna plan type before scheduling Asparlas infusions. The financial exposure on a denied specialty drug claim is significant.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| ALL or LBL, age ≤21, with multi-agent chemo | Covered | C91.0–C91.2, C83.50–C83.59; CPT 96413–96415 | Prior auth required; document full chemo regimen |
| Continuation of therapy (no toxicity, no progression) | Covered | C91.0–C91.2, C83.50–C83.59; CPT 96413–96415 | Document tolerability and response at each visit |
| ALL or LBL, age >21 | Not Covered | C91.0–C91.2, C83.50–C83.59 | Age threshold is a hard cutoff |
| Single-agent use (not with multi-agent chemo) | Not Covered | — | Does not meet multi-agent combination requirement |
| Any other indication | Experimental / Investigational | — | Aetna considers all other uses unproven |
Aetna Calaspargase Pegol Billing Guidelines and Action Items 2025
The effective date is November 6, 2025. These actions apply now.
| # | Action Item |
|---|---|
| 1 | Verify patient age before every Asparlas prior auth submission. Aetna's coverage policy requires the member to be 21 or younger. Pull the date of birth, calculate age at the start of therapy, and document it explicitly in the auth request. Don't assume the payer will calculate it — they won't. |
| 2 | Include the full multi-agent chemotherapy regimen in every prior auth request. A treatment order showing only Asparlas is not sufficient. Attach the complete protocol — drug names, dosing, and schedule. Aetna's reviewer needs to confirm the multi-agent requirement from the submitted documentation. |
| 3 | Update charge capture to link CPT 96413, 96414, and 96415 to the correct ICD-10 codes. For ALL, use C91.0 (acute lymphoblastic leukemia without mention of remission), C91.1 (in remission), or C91.2 (in relapse) depending on disease status. For LBL, use C83.50–C83.59 by site. The wrong ICD-10 pairing is one of the most common reasons for claim denial on specialty drug infusions. |
| 4 | Build continuation-of-therapy documentation into your infusion visit workflow. Every infusion note should address two things: absence of unacceptable toxicity and evidence of continued treatment response. This language maps directly to Aetna's continuation criteria. Vague progress notes create auth gaps. |
| 5 | Don't apply CPB 0957 criteria to Medicare-covered patients. This policy governs commercial plans only. Aetna Medicare members have separate Part B criteria. If your infusion center treats both commercial and Medicare patients on Asparlas, make sure your billing team knows which plan type each patient carries before submitting. |
| 6 | Flag any Aetna commercial patient aged 20–21 for close monitoring. These patients are at the boundary of the age cutoff. If therapy extends past their 22nd birthday, coverage eligibility changes. Set a trigger in your scheduling system to review Aetna prior auth status when a patient approaches the age threshold. |
| 7 | Consult your compliance officer if you treat adult ALL patients on Aetna commercial plans. Off-label adult use of Asparlas is not covered under CPB 0957. If your practice has patients aged 22 and older on Asparlas regimens billed to Aetna commercial, that's a financial and compliance exposure worth reviewing before submitting further claims. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Calaspargase Pegol Under CPB 0957
Covered CPT Codes (When Selection Criteria Are Met)
These codes cover IV infusion administration of Asparlas as part of a multi-agent chemotherapy protocol.
| Code | Type | Description |
|---|---|---|
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion |
Calaspargase pegol billing requires pairing these administration codes with the correct drug HCPCS code for Asparlas. CPB 0957 does not list a specific HCPCS drug code in the published policy data — confirm the Asparlas HCPCS code with your specialty pharmacy or drug billing team before submission.
Key ICD-10-CM Diagnosis Codes
All 13 diagnosis codes listed in CPB 0957 are covered indications when the age and multi-agent criteria are met.
| Code | Description |
|---|---|
| C83.50 | Lymphoblastic (diffuse) lymphoma, unspecified site |
| C83.51 | Lymphoblastic (diffuse) lymphoma, head, face, and neck |
| C83.52 | Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes |
| C83.53 | Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes |
| C83.54 | Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb |
| C83.55 | Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb |
| C83.56 | Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes |
| C83.57 | Lymphoblastic (diffuse) lymphoma, spleen |
| C83.58 | Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites |
| C83.59 | Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites |
| C91.0 | Acute lymphoblastic leukemia [ALL], not having achieved remission |
| C91.1 | Acute lymphoblastic leukemia [ALL], in remission |
| C91.2 | Acute lymphoblastic leukemia [ALL], in relapse |
One practical note: the C91 codes carry disease status specificity that matters for clinical documentation. "Not having achieved remission," "in remission," and "in relapse" aren't interchangeable on the claim. Make sure your coder is pulling the code that matches the physician's documented disease status — not defaulting to C91.0 for every claim.
Get the Full Picture for CPT 96413
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.